sST2与急性心力衰竭预后的meta分析

doi:10.3969/j.issn.1006-5253.2021.06.006

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1689 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the prognostic value of soluble growth stimulating gene 2 protein (sST2), a newly recommended marker of heart failure, in patients with acute heart failure.Methods Wanfang, VIP, CNKI and PubMed were searched with computers, and the Chinese and English literatures related to the evaluation of prognosis of acute heart failure by serum sST2 from the establishment of the database to January 31, 2021 were searched. Two evaluators independently screened the literature, extracted the data and evaluated the quality of the articles.Results sST2 was related to the poor prognosis of patients with acute heart failure. The risk of complex cardiovascular events (HR:1.79, 95%CI:1.44-2.22), all-cause death (HR:2.24, 95%CI:1.60-3.12), heart failure readmission (HR:1.31,95%CI:1.07-1.60) and cardiovascular death (HR:2.78, 95%CI:2.07-3.73) in patients with acute heart failure with elevated sST2 were higher than those with normal sST2. Subgroup analysis: there were differences in the prediction of end events between systolic blood pressure level≥19 kPa (140 mmHg) and systolic blood pressure level<19 kPa (140 mmHg) by sST2, and it was more predictive for end events with systolic blood pressure level<19 kPa (140 mmHg).Conclusion The incidence of adverse events in patients with acute heart failure with increased sST2 is significantly higher.

Key words： sST2 acute heart failure prognosis meta analysis

Received: 01 November 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Zhen
	Zhang Ning
	Shi Xinye
	Liu Jingyang
	Dong Wenjing
	Sun Jingwu

Cite this article:

Liu Zhen,Zhang Ning,Shi Xinye, et al. Meta analysis of sST2 and prognosis of acute heart failure[J]. journal1, 2021, 28(6): 508-512.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2021.06.006 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2021/V28/I6/508

［1］中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.急性心力衰竭基层诊疗指南:2019年［J］.中华全科医师杂志,2019,18(10):925-930.
［2］ALEKSOVA A, PALDINO A, BELTRAMI A, et al. Cardiac biomarkers in the emergency department: The role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome: There is meat on the bone［J］. J Clin Med, 2019, 8(2):270.
［3］BREIDTHARDT T, BALMELLI C, TWERENBOLD R, et al. Heart failure therapy-induced early ST2 changes may offer longterm therapy guidance［J］. J Card Fail, 2013, 19(12):821-828.
［4］FRI-ES F, LOUREN-O P, LASZCZYNSKA O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction［J］. Clin Res Cardiol, 2015, 104(6):491-499.
［5］LASSUS J, GAYAT E, MUELLER C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The multinational observational cohort on acute heart failure (MOCA) study［J］. Int J Cardiol, 2013, 168(3):2186-2194.
［6］JIN M, WEI S, GAO R, et al. Predictors of long-term mortality in patients with acute heart failure［J］. Int Heart J, 2017, 58(3):409-415.
［7］PASCUAL-FIGAL D A, MANZANO-FERN-NDEZ S, BORONAT M, et al. Soluble ST2, high-sensitivity troponin T and N terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure［J］. Eur J Heart Fail, 2011, 13(7):718-725.
［8］PASCUAL-FIGAL D A, BAYES-GENIS A, ASENSIO-LOPEZ M C, et al. The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure［J］. J Am Coll Cardiol, 2019, 73(9):1016-1025.
［9］TANG W H, WU Y P, GRODIN J L, et al. Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure［J］. JACC Heart Fail, 2016, 4(1):68-77.

［10］贺明轶,秦俭.血浆NT-proBNP、血清ST2与急性失代偿性心力衰竭预后评估［J］.成都医学院学报,2014,9(2):142-145.
［11］余宏斌,谭小红.sST-2水平在急性失代偿性心力衰竭患者预后判断中的价值［J］.检验医学与临床,2019,16(12):1706-1708.

［12］MARTIN N T, MARTIN M U. Interleukin 33 is a guardian of barriers and a local alarmin［J］. Nat Immunol, 2016, 17(2):122-131.
［13］MILLER A M, LIEW F Y. The IL-33/ST2 pathway: A new therapeutic target in cardiovascular disease［J］. Pharmacol Ther, 2011, 131(2):179-186.
［14］SCHMITZ J, OWYANG A, OLDHAM E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines［J］. Immunity, 2005, 23(5):479-490.
［15］TSIGKOU V, SIASOS G, BLETSA E, et al. The predictive role for ST2 in patients with acute coronary syndromes and heart failure［J］. Curr Med Chem, 2020, 27(27):4479-4493.
［16］SIASOS G, TOUSOULIS D, OIKONOMOU E, et al. Novel biomarkers in heart failure: Usefulness in clinical practice［J］. Expert Rev Cardiovasc Ther, 2014, 12(3):311-321.
［17］PASCUAL-FIGAL D A, JANUZZI J L. The biology of ST2:The international ST2 consensus panel［J］. Am J Cardiol, 2015, 115(7 Suppl):3B-7B.
［18］KAKKAR R, LEE R T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker［J］. Nat Rev Drug Discov, 2008, 7(10):827-840.
［19］DIEPLINGER B, MUELLER T. Soluble ST2 in heart failure［J］. Clin Chim Acta, 2015, 443:57-70.
［20］LOTIERZO M, DUPUY A M, KALMANOVICH E, et al. sST2 as a valueadded biomarker in heart failure［J］. Clin Chim Acta, 2020, 501:120-130.
［21］SANADA S, HAKUNO D, HIGGINS L J, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system［J］. J Clin Invest, 2007, 117(6):1538-1549.
［22］BOISOT S, BEEDE J, ISAKSON S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure［J］. J Card Fail, 2008, 14(9):732-738.